Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
We report the identification of a molecular signature using the Scano-miR profiling platform based on the differential expression of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (VHR) prostate cancer (PCa). Five miRNA PCa biomarkers (miR-200c, miR-605, miR-135a*, miR-433, and miR-106a) were identified as useful for differentiating indolent and aggressive forms of PCa. All patients with VHR PCa in the study had elevated serum levels of miR-200c. Circulating miR-433, which was differentially expressed in patients with VHR versus low-risk (LR) forms of PCa, was not detectable by quantitative real-time PCR in samples from healthy volunteers. In blind studies, the five miRNA PCa biomarkers were able to differentiate patients with VHR PCas from those with LR forms as well as healthy individuals with at least 89% accuracy. Biological pathway analysis showed the predictive capability of these miRNA biomarkers for the diagnosis and prognosis of VHR aggressive PCa.
Interdepartmental Biological Sciences Program, Northwestern University, Evanston, IL 60208; International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208;
Ali H
AH
Alhasan
International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208; Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208;
Alexander W
AW
Scott
Interdepartmental Biological Sciences Program, Northwestern University, Evanston, IL 60208;
Jia J
JJ
Wu
Health and Biomedical Informatics Division, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611;
Gang
G
Feng
Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611; chadnano@northwestern.edu joshua.meeks@northwestern.edu cthaxton003@northwestern.edu.
Joshua J
JJ
Meeks
International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208; Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611; Institute for BioNanotechnology and Medicine, Northwestern University, Chicago, IL 60611; chadnano@northwestern.edu joshua.meeks@northwestern.edu cthaxton003@northwestern.edu.
C Shad
CS
Thaxton
Interdepartmental Biological Sciences Program, Northwestern University, Evanston, IL 60208; International Institute for Nanotechnology, Northwestern University, Evanston, IL 60208; Department of Biomedical Engineering, Northwestern University, Evanston, IL 60208; Department of Chemistry, Northwestern University, Evanston, IL 60208 chadnano@northwestern.edu joshua.meeks@northwestern.edu cthaxton003@northwestern.edu.
Chad A
CA
Mirkin
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D000074166:Circulating MicroRNA / Q000097:blood* / Q000235:genetics; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000097:blood* / Q000235:genetics / Q000473:pathology; D012307:Risk Factors; D059467:Transcriptome
D014408:Biomarkers, Tumor; D000074166:Circulating MicroRNA
Scano-miR; biomarker; microRNA; prostate cancer; spherical nucleic acid